More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
Soliris (eculizumab) was found in a real-world setting to safely and effectively treat adults with generalized myasthenia gravis…
Blood levels of certain immune cells, called follicular helper T-cells (Tfh), are abnormally high in patients with myasthenia gravis (MG) …
High levels of autoantibodies against acetylcholine receptors (AChR) in the blood of people with thymoma — a tumor of the thymus —…
Lower frequency of a specific subset of immune cells in the bloodstream may help identify myasthenia gravis (MG) in…
Myasthenia gravis (MG) can develop in people with polycythemia vera (PV), a type of blood cancer, even in the…
A first person has been dosed in a Phase 2 trial evaluating mezagitamab (TAK-079), Takeda Pharmaceutical’s investigational antibody, as…
A Phase 2 clinical trial of Harbour BioMed‘s investigational therapy batoclimab, also known as HBM9161, for myasthenia…
NMD Pharma is launching a Phase 1/2a trial in the Netherlands to evaluate for the first time NMD670, an…